NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
01/07/2020
Back to search
Official data from USPTO
NASALCARE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
48
Latest update
01/07/2020
Trademark type
Combined
Nice classes
5
Filing date
06/22/2008
Registration date
09/29/2009
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/07/2020
Last transaction
01/07/2020
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
01/02/2007
First use in commerce
01/02/2007
Drawing code
3
Owner type
03
Owner location
Newport, DE
Examiner
BENJAMIN, SARA NICOLE
Law office
M10
Current location
GENERIC WEB UPDATE
Mark description
The mark consists of the wording "NASALCARE" with two curved lines representing air or vapor emanating from the "L".
Holders and representatives
Holders
TechWorld Corporation, Inc.
TechWorld Corporation, Inc.
Representatives
Lilly Zhang TechWorld Corporation, Inc.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in foodbeveragesanimal feed and pharmaceuticals; Antimicrobial preservatives for cosmetics and pharmaceuticals; Astringents; Bismuth preparations for pharmaceutical purposes; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of a coating for macromolecule agents that facilitate the delivery of a wide range of pharmaceuticals; Gelatin capsules sold empty for pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of allergy and respiratory tract infections; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Inhalers filled with anti-infectives and anti-allergy pharmaceuticals; Injectable pharmaceuticals for treatment of anaphylactic reactions; Intravenous fluids used for rehydrationnutrition and the delivery of pharmaceutical preparations; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders ; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; for the treatment of inflammatory disorders; for use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria-based diseasesfor the treatment of diabetesanti-infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccines ; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparationsantidepressants; Pharmaceutical preparationsappetite suppressants; Pharmaceutical preparationsa blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparationsa drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparationsanticoagulants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticalsanti-infectives; Pharmaceuticalsantihelmintics; Pharmaceuticalsinducers of erections; Pharmaceuticalslipid lowering agents; Plant extracts for medicalveterinary and pharmaceutical purposes; Potassium preparations for pharmaceutical purposes; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Synthetic peptides for pharmaceutical purposes; Unit dose capsules sold empty for pharmaceutical use; Vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry; Yeast or yeast extracts for medicalveterinary or pharmaceutical purposes
Publications
History of USPTO decisions and trademark events.
48 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
01/07/2020
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
01/07/2020
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
01/06/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/03/2020
PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
07/07/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/07/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/21/2019
E89R
TEAS SECTION 8 & 9 RECEIVED
06/21/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
09/29/2018
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
10/12/2016
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
10/12/2016
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
09/28/2016
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
09/27/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/06/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/27/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/08/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/03/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
03/28/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/25/2016
E815
TEAS SECTION 8 & 15 RECEIVED
03/25/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
12/13/2014
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
11/24/2014
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
10/06/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/06/2014
E815
TEAS SECTION 8 & 15 RECEIVED
09/30/2014
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/30/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
09/29/2009
TMBN
TTAB RELEASE CASE TO TRADEMARKS
08/26/2009
OP.T
OPPOSITION TERMINATED NO. 999999
08/26/2009
OP.D
OPPOSITION DISMISSED NO. 999999
08/26/2009
OP.I
OPPOSITION INSTITUTED NO. 999999
03/12/2009
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
02/04/2009
PUBO
PUBLISHED FOR OPPOSITION
01/20/2009
NPUB
NOTICE OF PUBLICATION
12/31/2008
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/16/2008
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/16/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/16/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/16/2008
ALIE
ASSIGNED TO LIE
12/16/2008
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/01/2008
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/01/2008
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/03/2008
GNRT
NON-FINAL ACTION E-MAILED
10/03/2008
CNRT
NON-FINAL ACTION WRITTEN
10/03/2008
DOCK
ASSIGNED TO EXAMINER
09/26/2008
MDSM
NOTICE OF DESIGN SEARCH CODE MAILED
06/26/2008
NWAP
NEW APPLICATION ENTERED
06/25/2008
Continuous trademark protection
Get notified about every new filing that threatens NASALCARE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.